. 2016 Jun 28;376(1):155-64.

doi: 10.1016/j.canlet.2016.03.037. Epub 2016 Mar 24.

Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer

Mingwei Chen¹, Chengle Zhuang², Yuchen Liu³, Jianfa Li², Fen Dai⁴, Ming Xia⁵, Yonghao Zhan², Junhao Lin², Zhicong Chen², Anbang He⁶, Wen Xu³, Guoping Zhao⁷, Yinglu Guo⁸, Zhiming Cai⁹, Weiren Huang¹⁰

Affiliations

¹ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Department of Urology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, Zhejiang Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China.
² Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Shantou University Medical College, Shantou 515041, Guangdong Province, China.
³ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China.
⁴ Anhui Medical University, Hefei 230032, Anhui Province, China.
⁵ Department of Urology, The Third Affiliated Hospital of Southen Medical University, Guangzhou 510630, Guangdong Province, China.
⁶ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China.
⁷ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai 200000, China.
⁸ Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China.
⁹ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China; Shantou University Medical College, Shantou 515041, Guangdong Province, China; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. Electronic address: caizhiming2000@163.com.
¹⁰ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China; Shantou University Medical College, Shantou 515041, Guangdong Province, China; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. Electronic address: pony8980@163.com.

PMID: 27018306
DOI: 10.1016/j.canlet.2016.03.037

Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer

Mingwei Chen et al. Cancer Lett. 2016.

. 2016 Jun 28;376(1):155-64.

doi: 10.1016/j.canlet.2016.03.037. Epub 2016 Mar 24.

Authors

Affiliations

¹ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Department of Urology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, Zhejiang Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China.
² Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Shantou University Medical College, Shantou 515041, Guangdong Province, China.
³ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China.
⁴ Anhui Medical University, Hefei 230032, Anhui Province, China.
⁵ Department of Urology, The Third Affiliated Hospital of Southen Medical University, Guangzhou 510630, Guangdong Province, China.
⁶ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China.
⁷ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai 200000, China.
⁸ Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China.
⁹ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China; Shantou University Medical College, Shantou 515041, Guangdong Province, China; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. Electronic address: caizhiming2000@163.com.
¹⁰ Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Anhui Medical University, The First Affiliated Hospital of Shenzhen University, Shenzhen 518039, Guangdong Province, China; Anhui Medical University, Hefei 230032, Anhui Province, China; Shantou University Medical College, Shantou 515041, Guangdong Province, China; Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China. Electronic address: pony8980@163.com.

PMID: 27018306
DOI: 10.1016/j.canlet.2016.03.037

Abstract

Various studies have indicated that long non-coding RNAs (lncRNAs) play vital roles in the cancer development and progression. LncRNA hypoxia inducible factor 1alpha antisense RNA-2 (HIF1A-AS2) is upregulated in gastric carcinomas and knockdown of HIF1A-AS2 expression by siRNA could inhibit cell proliferation in vitro and tumorigenesis in vivo. Inspired by these observations, we hypothesized that HIF1A-AS2 possibly plays the analogous roles in bladder cancer. In our study, we first reported that HIF1A-AS2 was up-regulated in bladder cancer tissues and cells, and HIF1A-AS2 expression level in bladder cancer tissues is positively associated with advanced clinical pathologic grade and TNM phase. Cell proliferation inhibition, cell migration suppression and apoptosis induction were observed by silencing HIF1A-AS2 in bladder cancer T24 and 5637 cells. Overexpression of HIF1A-AS2 in SV-HUC-1 cells could promote cell proliferation, cell migration and anti-apoptosis. Besides, we utilized the emerging technology of medical synthetic biology to design tetracycline-inducible small hairpin RNA (shRNA) vector which specifically silenced HIF1A-AS2 in a dosage-dependent manner to inhibit the progression of human bladder cancer. In conclusion, our data suggested that HIF1A-AS2 plays oncogenic roles and can be used as a therapeutic target for treating human bladder cancer. Synthetic "tetracycline-on" switch system that quantitatively controlled the expression of HIF1A-AS2 in bladder cancer can inhibit the progression of bladder cancer cells in a dosage-dependent manner. Our findings provide new insights into the role of the lncRNA HIF1A-AS2 in the bladder cancer.

Keywords: Bladder cancer; HIF1A-AS2; LncRNAs; Synthetic biology; Tetracycline-inducible.

PubMed Disclaimer

Cited by

Long Noncoding RNA (lncRNA)-Mediated Competing Endogenous RNA Networks Provide Novel Potential Biomarkers and Therapeutic Targets for Colorectal Cancer.
Wang L, Cho KB, Li Y, Tao G, Xie Z, Guo B. Wang L, et al. Int J Mol Sci. 2019 Nov 16;20(22):5758. doi: 10.3390/ijms20225758. Int J Mol Sci. 2019. PMID: 31744051 Free PMC article. Review.
CircAMOTL1 Promotes Tumorigenesis Through miR-526b/SIK2 Axis in Cervical Cancer.
Sun Z, Niu S, Xu F, Zhao W, Ma R, Chen M. Sun Z, et al. Front Cell Dev Biol. 2020 Dec 3;8:568190. doi: 10.3389/fcell.2020.568190. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33344445 Free PMC article.
Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review).
Shahid M, Yeon A, Kim J. Shahid M, et al. Mol Med Rep. 2020 Dec;22(6):5003-5011. doi: 10.3892/mmr.2020.11627. Epub 2020 Oct 22. Mol Med Rep. 2020. PMID: 33174036 Free PMC article. Review.
Long non-coding RNA RGMB-AS1 represses nasopharyngeal carcinoma progression via binding to forkhead box A1.
Zhang T, Jin Y, Luo X. Zhang T, et al. Bioengineered. 2022 Mar;13(3):5564-5580. doi: 10.1080/21655979.2022.2039495. Bioengineered. 2022. PMID: 35184697 Free PMC article.
Long Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications.
Huang QY, Liu GF, Qian XL, Tang LB, Huang QY, Xiong LX. Huang QY, et al. Cancers (Basel). 2019 Nov 16;11(11):1802. doi: 10.3390/cancers11111802. Cancers (Basel). 2019. PMID: 31744046 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer

Affiliations

Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical